Juvenile dermatomyositis, clinical manifestations and outcome in an Iranian cohort

Objective: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy of childhood and is characterized by proximal muscle weakness and pathognomonic skin rashes. In this study, we performed a descriptive cross sectional study to assess the clinical manifestations and outcomes of 39 pat...

Full description

Bibliographic Details
Main Authors: Massoud Saghafi, Zahra Rezaieyazdi, Kamila Hashemzadeh
Format: Article
Language:English
Published: SpringerOpen 2014-06-01
Series:Egyptian Pediatric Association Gazette
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1110663814000299
id doaj-f4b08302bed44a988d42df774bbd3ab8
record_format Article
spelling doaj-f4b08302bed44a988d42df774bbd3ab82020-11-25T02:14:21ZengSpringerOpenEgyptian Pediatric Association Gazette1110-66382014-06-01622465110.1016/j.epag.2014.06.001Juvenile dermatomyositis, clinical manifestations and outcome in an Iranian cohortMassoud SaghafiZahra RezaieyazdiKamila HashemzadehObjective: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy of childhood and is characterized by proximal muscle weakness and pathognomonic skin rashes. In this study, we performed a descriptive cross sectional study to assess the clinical manifestations and outcomes of 39 patients with JDM from the northeast of Iran during 12 years and compared our findings with other studies. Design: 39 patients (16 boys and 23 girls) with juvenile dermatomyositis were studied retrospectively between 2001 and 2013. Gender, age at disease onset and diagnosis, clinical manifestations, laboratory data at onset, treatment and outcome of these patients were reviewed. Measurements and results: The mean age of onset was 9.42 ± 3.85 years. At the time of presentation, muscle weakness occurred in 100%; heliotrope rash in 51.2%; gottron’s papules in 46.1%, calcinosis in 12.8%, and 87.1% had at least one abnormal muscle enzyme result. Muscle biopsy was performed in 15.3% and was abnormal in all. All patients received corticosteroids; but methotrexate, hydroxychloroquine, intravenous immunoglobulin, or azathioprine was added to corticosteroid in some patients. The mean follow-up period was 22.66 ± 23.53 months. Conclusions: This study was in parallel with other reviews except for calcinosis which was observed with lower frequency. It is suggested that delay in diagnosis and treatment may be associated with calcinosis.http://www.sciencedirect.com/science/article/pii/S1110663814000299Juvenile dermatomyositisInflammatory myopathySkin manifestationSubcutaneous calcification
collection DOAJ
language English
format Article
sources DOAJ
author Massoud Saghafi
Zahra Rezaieyazdi
Kamila Hashemzadeh
spellingShingle Massoud Saghafi
Zahra Rezaieyazdi
Kamila Hashemzadeh
Juvenile dermatomyositis, clinical manifestations and outcome in an Iranian cohort
Egyptian Pediatric Association Gazette
Juvenile dermatomyositis
Inflammatory myopathy
Skin manifestation
Subcutaneous calcification
author_facet Massoud Saghafi
Zahra Rezaieyazdi
Kamila Hashemzadeh
author_sort Massoud Saghafi
title Juvenile dermatomyositis, clinical manifestations and outcome in an Iranian cohort
title_short Juvenile dermatomyositis, clinical manifestations and outcome in an Iranian cohort
title_full Juvenile dermatomyositis, clinical manifestations and outcome in an Iranian cohort
title_fullStr Juvenile dermatomyositis, clinical manifestations and outcome in an Iranian cohort
title_full_unstemmed Juvenile dermatomyositis, clinical manifestations and outcome in an Iranian cohort
title_sort juvenile dermatomyositis, clinical manifestations and outcome in an iranian cohort
publisher SpringerOpen
series Egyptian Pediatric Association Gazette
issn 1110-6638
publishDate 2014-06-01
description Objective: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy of childhood and is characterized by proximal muscle weakness and pathognomonic skin rashes. In this study, we performed a descriptive cross sectional study to assess the clinical manifestations and outcomes of 39 patients with JDM from the northeast of Iran during 12 years and compared our findings with other studies. Design: 39 patients (16 boys and 23 girls) with juvenile dermatomyositis were studied retrospectively between 2001 and 2013. Gender, age at disease onset and diagnosis, clinical manifestations, laboratory data at onset, treatment and outcome of these patients were reviewed. Measurements and results: The mean age of onset was 9.42 ± 3.85 years. At the time of presentation, muscle weakness occurred in 100%; heliotrope rash in 51.2%; gottron’s papules in 46.1%, calcinosis in 12.8%, and 87.1% had at least one abnormal muscle enzyme result. Muscle biopsy was performed in 15.3% and was abnormal in all. All patients received corticosteroids; but methotrexate, hydroxychloroquine, intravenous immunoglobulin, or azathioprine was added to corticosteroid in some patients. The mean follow-up period was 22.66 ± 23.53 months. Conclusions: This study was in parallel with other reviews except for calcinosis which was observed with lower frequency. It is suggested that delay in diagnosis and treatment may be associated with calcinosis.
topic Juvenile dermatomyositis
Inflammatory myopathy
Skin manifestation
Subcutaneous calcification
url http://www.sciencedirect.com/science/article/pii/S1110663814000299
work_keys_str_mv AT massoudsaghafi juveniledermatomyositisclinicalmanifestationsandoutcomeinaniraniancohort
AT zahrarezaieyazdi juveniledermatomyositisclinicalmanifestationsandoutcomeinaniraniancohort
AT kamilahashemzadeh juveniledermatomyositisclinicalmanifestationsandoutcomeinaniraniancohort
_version_ 1724900178738020352